Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Sponsors

Lead Sponsor: Y-mAbs Therapeutics

Collaborator: Memorial Sloan Kettering Cancer Center

Source Y-mAbs Therapeutics
Brief Summary

The purpose of this study is to test the safety of a new method to treat Diffuse Intrinsic Pontine Glioma (DIPG). The researchers will use "convection-enhanced delivery" (CED) to deliver an agent called 124I-omburtamab. CED is performed during surgery. The study agent is infused through a small tube placed into the tumor in the brain. Many studies have shown this can safely be done in animals but this study is the first time 124I-omburtamab will be given by CED in humans. This will be one of the first times that CED has been performed in the brain stem. Omburtamab is something called an antibody. Antibodies are made by the body to fight infections and sometimes cancer. The antibody omburtamab is produced by mice and can attack many kinds of tumors. A radioactive substance, 124I-omburtamab, is attached to omburtamab. 124I-omburtamab sticks to parts of tumor cells and can cause the tumor cells to die from radiation. Studies have also been done on humans using 124I-omburtamab to treat other kinds of cancer. Our studies of some DPG and related tumors suggest that omburtamab will bind to the tumor, but the investigators don't know that for sure. In this study, the researchers want to find out how safe 124I-omburtamab given by CED is at different dose levels. They will look to see what effects (both good and bad) it has on the patient. The dose of 124I-omburtamab will increase for each new group of patients. The procedure has already been safely performed with lower doses and infusion volumes in a number of patients here at MSKCC. The amount they get will depend on when they enter the study. If too many serious side effects are seen with a certain dose, no one will be treated with a higher dose, and some more patients may be treated with a lower dose to make sure that dose is safe.

Overall Status Recruiting
Start Date 2011-12-01
Completion Date 2021-12-01
Primary Completion Date 2021-12-01
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
maximum tolerated dose 2 years
assess the toxicity profile 2 years
Secondary Outcome
Measure Time Frame
overall survival 2 years
Enrollment 64
Condition
Intervention

Intervention Type: Drug

Intervention Name: Radioactive iodine-labeled monoclonal antibody omburtamab

Description: Prior to treatment children will be pre-medicated with super-saturated potassium iodide & liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-omburtamab into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-omburtamab. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations & PET/CT or PET/MRI scans of the brain & other organs. Clinical observations, intensive care unit monitoring, routine blood & interval imaging studies (MRI & PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.

Arm Group Label: Radioactive iodine-labeled monoclonal antibody omburtamab

Intervention Type: Radiation

Intervention Name: External Beam Radiotherapy

Description: Standard radiation therapy is given 4-6 weeks prior to study entry.

Arm Group Label: Radioactive iodine-labeled monoclonal antibody omburtamab

Eligibility

Criteria:

Inclusion Criteria: - Consensus of diagnosis must be reached by a multidisciplinary pediatric neuro-oncology team by considering both clinical evidence and MRI presentation. Tissue diagnosis is not required. - The patient must have undergone prior external beam radiotherapy to a dose of 54-60 Gy to the brain stem. At least 4 weeks but no more than 14 weeks must have elapsed from the completion of radiotherapy. - The patient must be in adequate general condition for study, with Lansky or Karnofsky Performance Score of ≥ 50 at study entry . Lansky Performance scale will be used for patients ≤16 years of age. - The patient must be ≥ 2 and ≤ 21 years old. - Patient must weigh a minimum of 8 kg. Exclusion Criteria: - Clinical and/or radiographic (MRI) progression of tumor following external beam radiation therapy. - Metastatic disease. - Untreated symptomatic hydrocephalus determined by treating physician. - AST or ALT > 2x the upper limit of normal. - Platelets < 100,000/mcL. - ANC < 1000/mcL. - Abnormal PT (Inr) >1.5 INR or PTT > 42 sec (may be corrected with FFP, cryoprecipitate, vitamin K, etc). - Total bilirubin > 2.0 mg/dl. - Serum creatinine > 1.5x the upper limit of normal for age, or calculated creatinine clearance or nuclear GFR < 70 ml/min/1.73 m2.

Gender:

All

Minimum Age:

2 Years

Maximum Age:

21 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Mark Souweidane, MD Principal Investigator Memorial Sloan Kettering Cancer Center
Overall Contact

Last Name: Mark Souweidane, MD

Phone: 212-639-2336

Location
Facility: Status: Contact:
Weill Medical College of Cornell University | New York, New York, 10021, United States Not yet recruiting Maria Donzelli, PNP 212-639-2336
Memorial Sloan Kettering Cancer Center | New York, New York, 10065, United States Recruiting Maria Donzelli, PNP 212-639-2336 Mark Souweidane, MD Principal Investigator
Location Countries

United States

Verification Date

2021-06-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Radioactive iodine-labeled monoclonal antibody omburtamab

Type: Experimental

Description: This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Other

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News